58P Validation of the Achilles VELOS process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T-cells

Autor: Samuel, E.R., Rologi, E., Fraser, H., Sassi, M., Pruchniak, M., Kotsiou, E., Robinson, J., Benzekhroufa, K., Goodsell, L., Carolan, C., Saggese, M., Grant, M., Samways, B., Kotecha, P., Schmitt, A., Lawrence, D., Forster, M., Turajlic, S., Lowdell, M., Quezada, S.

Publikováno v: In Annals of Oncology December 2021 32 Supplement 7:S1396-S1397

GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE

Autor: Araf, S., Wang, J., Pangault, C., Kotsiou, E., Hoxha, E., Iqbal, S., Davies, J., Johnson, P., Gribben, J., Graham, T., Chelala, C., Fest, T., Fitzgibbon, J., Okosun, J.

Publikováno v: Haematologica
Haematologica, Ferrata Storti Foundation, 2016, 101, pp.270--270
Haematologica, 2016, 101, pp.270--270

International audience; 21st Congress of the European-Hematology-Association, June 2016, Copenhagen, DENMARK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f460cb0dcf38e70e6fb5c6c34b80daac
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01359397

Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.

Autor: Araf S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk.; Centre for Genomic Health, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk., Wang J; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Korfi K; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Pangault C; UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France., Kotsiou E; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Rio-Machin A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Rahim T; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Heward J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Clear A; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Iqbal S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Davies JK; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Johnson P; Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK., Calaminici M; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Montoto S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Auer R; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Chelala C; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Gribben JG; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Graham TA; Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK., Fest T; UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France., Fitzgibbon J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Okosun J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. j.okosun@qmul.ac.uk.

Publikováno v: Leukemia [Leukemia] 2019 Jun; Vol. 33 (6), pp. 1540.

Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.

Autor: Gamal, Wael^1,2 (AUTHOR), Mediavilla-Varela, Melanie¹ (AUTHOR), Uriepero-Palma, Angimar¹ (AUTHOR), Pinilla-Ibarz, Javier^1,3 (AUTHOR), Sahakian, Eva^1,3 (AUTHOR) eva.sahakian@moffitt.org

Publikováno v: International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 12, p6324. 14p.

Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma.

Autor: Zhou, Yanjun¹ (AUTHOR) zyjmed@yeah.net, Qin, Xue² (AUTHOR), Hu, Qunchao³ (AUTHOR), Qin, Shaolei² (AUTHOR), Xu, Ran⁴ (AUTHOR), Gu, Ke¹ (AUTHOR) YourprofGUKE@126.com, Lu, Hua⁴ (AUTHOR) LHua1987@outlook.com

Publikováno v: Scientific Reports. 2/16/2024, Vol. 14 Issue 1, p1-16. 16p.